Psy155 - Determining the Value of Emicizumab (Hemlibra®) for the Prophylaxis Treatment of Haemophilia a Patients With Inhibitors in Spain by Multi-Criteria Decision Analysis (Mcda)
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2729
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV